SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending with strong bullish sentiment following recent significant revenue growth and Saudi FDA approval for its cancer treatment, with investors buzzing about Dr. Patrick Soon-Shiong's presentations and the potential for a massive short squeeze.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending due to its strategic pivot from Bitcoin mining to a high-performance computing and AI data center provider, backed by significant power infrastructure acquisitions and bullish institutional coverage. The community is actively discussing its high short interest and long-term growth potential as an AI infrastructure play, amidst varying views on short-term price action.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is trending amidst a highly volatile session, fueled by Citron Research announcing a short position that challenges the strong demand narrative in the AI-driven memory and storage sector. The community is sharply divided between those betting on a short squeeze and those warning of overvaluation and a potential market correction.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending as investors anticipate its upcoming earnings report, widely expected to mark its 18th consecutive beat and raise, with many hoping for its first positive GAAP EPS. Despite a broader software sector sell-off fueled by AI fears, the community highlights Zeta's proprietary data moat, AI capabilities, and OpenAI partnership as key drivers for its undervalued position and potential for a significant short squeeze.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is actively discussed as reports from peers like Samsung indicate surging HBM4 memory prices, strengthening the bullish conviction among the community regarding an accelerating AI-driven memory supercycle that is driving demand.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health Inc is trending following a mixed earnings report and cautious guidance, which initially prompted analyst downgrades and a sharp decline. However, strong "buy the dip" activity and high short interest are now driving a significant rebound, with the community actively discussing the potential for a short squeeze.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining, now Cipher Digital, is drawing significant attention after its earnings call underscored a successful pivot to AI/HPC data centers, showcasing on-schedule builds and an expanding pipeline of hyperscaler deals, which overshadows its Q4 financial miss. The community is actively discussing the strategic re-rating potential, driven by confirmed multi-billion dollar contracts and anticipation of new "imminent" agreements.

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Vir Biotechnology Inc

Vir Biotechnology is actively trending after announcing a major collaboration with Astellas Pharma for its prostate cancer immunotherapy asset, VIR-5500, which is supported by positive Phase 1 data and several analyst upgrades. The market is buzzing with discussions about the stock's short-squeeze potential, fueled by substantial partnership payments and its reportedly high short interest.

Rich Sparkle Holdings Ltd. engages in the provision of financial printing and corporate services. The firm offers typesetting, proofreading, translation, design, and printing of listing documents, financial reports, fund documents, circulars, and announcements. It also delivers advisory services, such as conducting internal control assessment and environmental, social and governance performance evaluation, and other services including provision of co-working space. The company was founded in 2016 and is headquartered in Hong Kong.

Rich Sparkle Holdings Ltd.

Rich Sparkle Holdings Limited

ANPA is trending following the completed acquisition of TikTok icon Khaby Lame's core company, driving intense speculation around its potential for explosive gains as a low-float Hong Kong stock, while a significant portion of the community warns of an unsustainable valuation and potential for a sharp decline.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is trending following a significant stock drop sparked by a reported net loss and cautious revenue outlook, despite strong top-line growth. The community is sharply divided, with bulls viewing the sell-off as a deep value opportunity ripe for a short squeeze, while bears highlight persistent profitability concerns and the broader challenges of the buy-now-pay-later model.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales

Axsome misses Q4 estimates for earnings. Revenues jump 65% on strong Auvelity sales as well as other product sales and top estimates.

Amicus' Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues

FOLD's Q4 earnings miss, but revenues beat estimates on strong Galafold and Pombiliti sales. The company is set to be acquired by BioMarin for $4.8 billion.

FDA Accepts Roche's NDA Seeking Approval for Breast Cancer Drug

FDA's acceptance of RHHBY's NDA for giredestrant plus everolimus in ER-positive breast cancer sets up a potential first oral SERD combo.

Viatris Stock to Report Q4 Earnings: What's in the Cards?

VTRS gears up for Q4 results amid Indore import alert, segment revenue pressure and steady margins as shares surge 39.7% in a year.

Insmed Lags on Q4 Earnings, Stock Gains on 2026 Brinsupri Sales View

INSM shares jump 7% as Brinsupri sales surge and 2026 outlook calls for at least $1B, despite a wider Q4 loss and rising expenses.

Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down

MDGL swings to a wider Q4 loss as expenses surge, but Rezdiffra sales top estimates and fuel revenue growth. The stock slides 11% in response to the mixed nature of the results.

Castle Biosciences (NASDAQ:CSTL) Stock Price Down 7% - Should You Sell?

Castle Biosciences (NASDAQ:CSTL) Trading Down 7% - Should You Sell...

BHC Stock Down on Q4 Earnings Miss, Salix Drives Revenue Growth

Bausch stock slips as Q4 EPS misses despite 9% revenue growth, strong Salix and Bausch + Lomb gains, and an upbeat 2026 sales outlook.

Castle Biosciences, Inc. (CSTL) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Castle Biosciences (CSTL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Collegium Pharmaceutical to Report Q4 Earnings: What's in the Cards?

COLL gears up to report Q4 earnings. Strong Jornay PM demand and higher pain portfolio sales fuel investor expectations ahead of its Feb. 26 report.

Castle Biosciences, Inc.is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, barrett’s esophagus, uveal melanoma, and in the treatment of mental health conditions. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.

Castle Biosciences Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

Ahead of earnings, sentiment is split between blowout AI growth and concerns around macro pressure, positioning, and post-ER volatility. How do you see it playing out?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.26	--	--	N/A
Q3 '25	-$0.52	-$0.02	96.16%	BEAT
Q2 '25	-$0.53	$0.15	128.24%	BEAT
Q1 '25	-$0.07	-$0.90	-1195.95%	MISSED
Q4 '24	$0.05	$0.32	579.25%	BEAT

CSTL
Castle Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest CSTL News

CSTLCastle Biosciences Inc